Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Biohaven Pharma (BHVN) Misses Q1 EPS by 15c, Revenues Beat
May 10, 2021 7:33 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.97), $0.15 worse than the analyst estimate of ($2.82). Revenue for the quarter came in at $43.82 million versus the consensus estimate of $40.63 million.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "NURTEC ODT's performance, with its... More
